Massivemarkets

SEC Form 4

BridgeBio Pharma, Inc. (BBIO) insider trading

In the 12 months to Nov 19, 2026, 8 BBIO insiders reported open-market sales of $93.5M across 33 filings; no open-market purchases were filed.

Latest filing · Last 12 months · Source: SEC EDGAR · How we count

Open-market sales
$93.5M
33 filings · 8 insiders
Open-market purchases
$0
0 filings
Pre-arranged sales (10b5-1)
32 of 33
$87.2M of $93.5M sold (93%)

Who traded BBIO, and when

  • Sale
  • Sale, pre-arranged (10b5-1)

BBIO daily close from Nov 19, 2025 to Nov 18, 2026, between $63.30 and $90.17, last $78.01. 33 sale and 0 purchase filings by 8 insiders, marked at their filing dates. Neil Kumar, Chief Executive Officer: sold $52.2M across 13 filings, first filed Nov 24, 2025, last Sep 21, 2026. Jennifer E. Cook, Director: sold $21.9M across 3 filings, first filed Jun 17, 2026, last Jul 13, 2026. Andrew Lo, Director: sold $6.3M across 1 filing, first filed Nov 19, 2025, last Nov 19, 2025. Andrea Ellis, Director: sold $5.7M across 2 filings, first filed Mar 6, 2026, last Jul 13, 2026. Hannah Valantine, Director: sold $2.7M across 3 filings, first filed Mar 3, 2026, last Jun 24, 2026. Randal W. Scott, Director: sold $2.1M across 3 filings, first filed Nov 19, 2025, last May 19, 2026. 2 others: sold $2.7M across 8 filings, first filed Dec 10, 2025, last Nov 3, 2026.

Largest mark · tap a row for others

Jennifer E. Cook · Director

Sale $13,156,008

148,589 shares at $88.54 avg

Filed Jul 13, 2026 · traded Jul 9

Pre-arranged (10b5-1) · close on filing date $83.08

BBIO daily closelast $78.01

Neil Kumar · Chief Executive Officer

$52.2M sold

Jennifer E. Cook · Director

$21.9M sold

Andrew Lo · Director

$6.3M sold

Andrea Ellis · Director

$5.7M sold

Hannah Valantine · Director

$2.7M sold

Randal W. Scott · Director

$2.1M sold

2 others

$2.7M sold
One row per insider, smaller filers combined; marks sit at the SEC filing date, sized by dollar value.

Open-market trades

33 filings in the last 12 months
Other insider activity (not market trades) · 61 records
  • Option exercises31 records
  • Tax withholding16 records
  • Grants and awards14 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

How to read this page

Open-market purchase or sale
A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
Pre-arranged (10b5-1)
The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
Filing date
Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

Frequently asked questions

Has BridgeBio Pharma, Inc.'s CEO sold stock?

Yes. Neil Kumar (CEO) sold 725,303 shares ($52.2M) between Nov 2025 and Sep 2026, all under a pre-arranged 10b5-1 plan.

How current is BBIO’s insider data?

These are BBIO Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

Build with AI

Track BBIO insider trades with your agent

This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:

Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BBIO every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.